Ten year retrospective analysis of BOP (bleomycin, vincristine, predinisone)-A novel non-myelosuppressive chemotherapy regimen for treatment of non-Hodgkin's lymphoma.


17560 Background: Non-Hodgkin's Lymphoma (NHL) represents the most common hematological malignancy in North America. Patients with advanced NHL, particularly those with pancytopenia, often do not tolerate the myelosuppressive side effects of chemotherapy. BOP (Bleomycin 10 mg/m2 IV D1, Vincristine 1.4 mg/m2 (max 2 mg) D1 and Prednisone 100 mg PO on D1,3,5… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics